The clinical correlates and risk profile of prediabetes (fasting plasma glucose (FPG) values in the upper normal limits but below the diabetic threshold) in hypertension, an insulin-resistant, prodiabetogenic condition, are scarcely known. For this reason, we evaluated 982 non-diabetic (FPG,o126 mg 100 ml À1 and no antidiabetic treatment) referred hypertensive patients without a history of cardiovascular disease grouped by mild (100-109 mg 100 ml
À1
) and advanced (110-125 mg 100 ml
) dysglycaemia compared with normal FPG (o100 mg 100 ml À1 ). FPG, total and high density lipoprotein (HDL) cholesterol, triglycerides and total white blood cell count were assessed by standard methodologies; 10-year predicted coronary heart disease (CHD) risk was approximated by the Framingham risk score (FRS). Metabolic syndrome (MetS) was diagnosed by standard categorical criteria using either 110 or 100 mg 100 ml À1 as a threshold for impaired fasting glucose (IFG). FPG was above 110 in 13% and between 100 and 109 in 20% of patients. In both dysglycaemic groups, perturbed glucose homeostasis
Introduction
Abnormalities of glucose homeostasis are common in essential hypertension, 1 an insulin resistant state 2 and an independent risk factor for diabetes, 3 whose prognostic outlook deteriorates after the onset of frank diabetes. 4 For those reasons, the interest towards a better understanding of subclinical increments in fasting plasma glucose (FPG) in nondiabetic hypertensive patients and their connection with conventional and non-conventional cardiovascular risk factors is high and growing. Impaired fasting glucose (IFG, dysglycaemia) , that is FPG values in the upper normal limits but below the diabetic threshold, is a prediabetic category created in 1997 to improve the early identification of people at increased risk of diabetes. 5 Limits for IFG, originally set in the 110-125 mg 100 ml À1 interval, 5 were lowered to 100-125 mg 100 ml À1 in 2003 by the American Diabetes Association in an effort to increase the sensitivity of that parameter for screening of individuals at risk of future diabetes and, possibly, cardiovascular events. 6 In recognition of its clinical and pathophysiological relevance, FPG above 100 mg 100 ml À1 has been included among the major risk factors in the 2007 guidelines jointly released by the ESH (European Society of Hypertension) and by the ESC (European Society of Cardiology). 7 Despite that important endorsement, however, one has to recognize our still scarce knowledge about the distribution and clinical correlates of different degrees of IFG in hypertension. As a matter of fact, the existing evidence about prediabetes in hypertension relies mainly upon impaired glucose tolerance, 8, 9 a pathophysiologically distinct prediabetic condition. 10 On the basis of the above considerations, we analysed a large group of non-diabetic hypertensive patients without a history of cardiovascular disease referred to our unit during the last years categorized by either mild (FPG 100-109 mg 100 ml À1 ) or more advanced (FPG 110-125 mg 100 ml À1 ) disturbances of glucose homeostasis compared with normal FPG (o100 mg 100 ml À1 ).
Materials and methods

Patients
Data refer to 982 non-diabetic hypertensive subjects (see Table 1 ). Systolic (S) and diastolic (D; phase V Korotkoff) BP was the mean of two measurements in sitting position by mercury sphygmomanometer after at least 20 min of rest using the appropriate cuff size.
Definitions
Metabolic syndrome (MetS) was diagnosed according to either the 2001 NCEP (National Cholesterol Education Programme)-ATP (adult treatment panel)-III, 11 or the 2005 AHA (American Heart Association)/NHLBI (National Heart, Lung and Blood Institute) definition, 12 the latter endorsed by the 2007 ESH/ESC hypertension guidelines. 7 The two definitions of MetS overlap (BP4130/85 mm Hg, triglyceridesX 150 mg 100 ml
À1
, HDL-C o40 mg 100 ml À1 in men and o50 mg 100 ml À1 in women, abdominal obesity), except different cutoffs for IFG (110 and 100 mg 100 ml À1 respectively). As, by selection, all patients were hypertensive (BP 4140/90 or being on antihypertensive treatment), and hence fulfilled at least one of the criteria for MetS, diagnosis required at least two of the remaining parameters. BMI X29.5 and X27.2 kg/m 2 in men and women, respectively, were the threshold for abdominal obesity, as those values corresponded to 102 cm in men, and 88 cm of waist circumference in a regression of BMI on waist (r ¼ 0.84, Po0.001) as validated in 100 hypertensive patients (50 men, age 58±12 years) by simultaneous recording of both parameters.
Absolute coronary heart disease (CHD) risk at 10 years was quantified by the NCEP-ATP-III Framingham risk score (FRS) system, 11 an algorythm derived from continuous variable multivariate risk equations to determine the short-term risk for developing a 'hard' CHD event (myocardial infarction or sudden cardiac death). The FRS system sums the weighted scores assigned to each of the following predictors: gender, age (20-79 years), systolic BP levels, being on antihypertensive treatment or not, total-C levels, HDL-C levels and smoking status.
Triglyceride, total-C and LDL-C X200, 240 and 160 mg 100 ml
, respectively, and HDL-C o40 mg were considered abnormal. 11 Upper quartile WBC count (47.7 Â 10 3 ) was considered high. BMIX30 kg/ m 2 and FRS 420% were the cutoffs for obesity and high CHD risk, respectively. 11 Smokers were current smokers independent of the number of cigarettes per day as opposed to never-and previous smokers (quitting tobacco for at least 6 months).
Statistics
One-way analysis of variance adjusted for confounders through the analysis of covariance and Bonferroni's test for multiple comparisons were used to assess the differences between groups. Categorical and ordinal parameters were tested by w 2 -or CochranArmitage (P-for-trend) statistics, respectively. Logistic regression analyses tested the association between FPG categories and categorical risk factors (0 ¼ absent, 1 ¼ present); strength of statistical association was estimated by crude or age-and gender-adjusted odds ratios and 95% confidence interval. Unless otherwise specified, descriptive statistics were mean±s.d., median (interquartile range) for skewed data and percentages for categorical variables. A Po0.05 was the limit of statistical significance.
Results
Higher FPG, triglycerides, WBC, lower HDL-C, worse CHD risk profile and more frequent smoking habits characterized men as opposed to greater prevalence of higher total-C and systolic BP in women. Age, BMI, diastolic BP, LDL-C, percentages of patients on antihypertensive and lipid-lowering treatment and frequency of MetS did not differ by gender (Table 1 , centre and right-hand columns).
Of 892 total patients, 134 (13%) had an FPG level of 110-125 mg 100 ml
À1
, 192 (20%) had an FPG level of 100-109 mg 100 ml À1 and 652 (67%) had an FPG level o100 mg 100 ml À1 (Table 2) . Individuals with FPG concentration at or above 100 mg 100 ml À1 were more likely to be men when compared with those with glucose o100 mg 100 ml
. With progressive increase in glucose concentration, individuals also tended to be older, heavier with increased triglycerides, decreased HDL-C and higher FRS (Table 2) .
Obesity, low HDL-C, abnormal triglycerides and high CHD risk were distinctly more frequent (Po0.001) in the two dysglycaemic categories (Figure 1) .
The overall frequency of MetS by NCEP-ATP-III criteria 11 was 34% (n ¼ 336) with a graded relationship to increasing FPG categories (Figure 2 ). Application of the AHA/NHLBI criteria 12 increased the overall rate to 44% (n ¼ 411, Po0.001) with a more than doubled prevalence in the group of patients with milder degree of dysglycaemia (Figure 2) .
The WBC count was highest in those with FPGX 110 mg 100 ml À1 (Table 2) , a trend persisting after accounting for age, gender, BMI, triglycerides and HDL-C by analysis of covariance.
Total C, LDL-C, BP, percentages of active smokers and patients on antihypertensive and lipid-lowering treatment were unrelated to glucose levels ( Table 2) . Table 3 shows percentages and odds ratios (crude and age, gender-adjusted) for several relevant variables by glucose category with FPGo100 mg 100 ml À1 as referent. The prevalence of most variables, except total-C and LDL-C (not shown), was significantly increased in subjects with FPG in the 110-125 and 100-109 intervals with widely overlapping 95% confidence interval indicating no significant differences between the two groups.
Discussion
This retrospective scrutiny of a large group of consecutive, non-diabetic, hypertensive referrals Dysglycaemia in hypertensionwithout a history of cardiovascular disease shows a tight link of mild and advanced dysglycaemia with hypertriglyceridaemia, low HDL-C and obesity, that is, the phenotypic hallmarks of insulin resistance. 13 That aggregation of cardiometabolic risk factors for CHD 14 likely reflects the intricate underlying interactions by which dyslipidaemia anticipates both hypertension 15 and frank hyperglycaemia, 16 and in turn, higher BP predicts both glucose intolerance and diabetes. 3, 17 Notably, lipid abnormalities, obesity and adverse cardiovascular risk profile were homogeneously distributed across the two 110-125 and 100-109 mg 100 ml À1 intervals in contrast with the attenuated prevalence of risk factors in the latter category emerging from previous cross-sectional analyses. 18 The discrepancy may relate to different lifestyle habits, ethnic backgrounds, the all-hypertensive and referred vs mixed normo-hypertensive community-based composition of the two samples. An additional point of interest of our data relates to the influence of different definitions of IFG on the prevalence of MetS, a high-risk phenotype in hypertension. 19 Compared with the more restrictive 110 mg 100 ml À1 11 in fact, lowering the threshold to 100 mg 100 ml À1 12 , increased the overall rate of MetS by about one-tenth and more than doubled the number of patients in the intermediate FPG 100-109 interval, qualifying for that diagnosis. Notably, however, more recent consensus documents favour FPG in the 110-125 mg 100 ml , low high density lipoprotein cholesterol (HDL-C, o40 mg 100 ml À1 ), high triglycerides (Trig; X200 mg 100 ml À1 ) and high coronary heart disease (CHD) risk (Framingham risk score420%) by fasting plasma glucose (FPG) levels (o100 mg 100 ml À1 , n ¼ 652 ; 100-109 mg 100 ml À1 , n ¼ 196 ; 110-125 mg 100 ml À1 , n ¼ 135 ). P-for-trend ! o0.01, *o0.001. See Table 3 
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predicting tool for new diabetes, 20 as FPG levels in the 100-110 mg 100 ml À1 range are weak, and statistically not significant predictors of cardiovascular risk, 18, [21] [22] [23] while increasing substantially the proportion of individuals labelled as prediabetic. 24 Moreover, although the 2007 ESH/ESC hypertension guidelines 7 equated MetS to target organ damage and diabetes as risk modifier, the value of a formal diagnosis of MetS in clinical practice is contentious 25 and may not overcome the contribution of its individual components for both diabetes prediction and determination of vascular risk. 26 An additional correlate of dysglycaemia was a higher FRS and an increased representation of patients at predicted CHD risk420% per 10 years, a level equivalent to a person with preexisting CHD. 11 The pattern confirms the clustering of conventional and 'non-conventional' risk factors in the same hypertensive individual, 27 a pattern strongly influenced by the presence of an obvious trend to a more adverse metabolic profile in men than women. In agreement with the overall picture and in line with earlier reports, 28 dysglycaemia also associated with higher WBC, an index of subclinical inflammation and an independent marker of future cardiovascular events, 29 a trend suggestive of some direct link between subclinical inflammation, perturbed glucose homeostasis and insulin resistancerelated metabolic abnormalities. 30 Consistent with the notion of glucose abnormalities and hypertension as related conditions, 1 about 15% of our patients had prediabetes on the basis of more restrictive (FPGX 110 mg 100 ml À1 ) definitions of IFG, 5 a figure three-to fourfold higher than that expected in middle aged, non-diabetic, healthy Italian populations. 31 In that subgroup of patients, conversion to type 2 diabetes, particularly if coexisting with impaired glucose tolerance, 32 is a likely 10 and ominous 4, 22 event, prompting lifestyle modifications 33 and, possibly, pharmacologic treatments 34 to avert that outcome. Abstinence from specific Not adjusted for age and gender because both parameters contribute to FRS determination.
antihypertensive drugs, such as b-adrenoceptor blocking agents 3, 35 in favour of renin-angiotensin system inhibitors 35 may be helpful, although those latter compounds are neutral when compared with placebo. 36, 37 Recent evidence also supports the concept of FPG as a continuous risk factor for cardiovascular disease, 33 similar to smoking, BP and dyslipidaemia, but the benefits of targeting highnormal FPG for cardiovascular prevention are to be assessed by specific randomized clinical trials.
The present results are subject to some limitations. First, data obtained in a retrospective survey of hypertensive referrals may not apply to the hypertensive population at large or to subjects with different ethnic and lifestyle backgrounds. Second, glucose assay was not centralized and, although most of the laboratories in our reference areas take advantage of a centralized quality control (see methods section), lack of standardization may have introduced some bias. We also categorized our patients on a single FPG subject to variability, although that procedure is foreseen to diagnose prediabetes in the absence of severe metabolic stress or illness. 10 Third, the adverse risk profile associated with increasing FPG may be conferred by impaired glucose tolerance rather than be a function of any particular FPG threshold. 38 Moreover, FPG values still within normal limits do not exclude undiagnosed diabetes. 10 Fourth, we used a validated BMI cutoff as a substitute for abdominal obesity in the MetS, as there is now agreement about the validity of that surrogate approach. 39 Fifth, a substantial portion of our patients was on antihypertensive treatment with a possible impact of some specific drug classes on metabolic variables, 3, 35 but unfortunately our records were not detailed enough to draw meaningful statistics on this point. An additional limitation relates to the imprecision of Framingham's CHD risk algorithms as predicting tools when applied to European hypertensive patients. 40 However this is a more general criticism that does not apply to our cross-sectional comparisons carried out by identical standards and in the same population.
